CRDF
Cardiff Oncology, Inc.Multiple drugs being tested (Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib) - no single lead drug identified from filing modulates Not explicitly stated; inferred targets include MEK (Cobimetinib), PARP (Olaparib, Saruparib), PLK1 (Onvansertib) to treat Pancreatic ductal adenocarcinoma (PDAC) - multiple stages including locally advanced, metastatic, resectable, and borderline resectable.
moa:Not explicitly stated; appears to involve targeted pathway inhibition using multiple mechanisms including MEK inhibition, PARP inhibition, and PLK1 inhibition
Non-randomized, single-arm Phase 1 trial with multiple intervention arms testing 5 different targeted therapies (Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib) in patients with pancreatic ductal adenocarcinoma across various stages; enrollment target 90 patients
primary endpoint:Proportion of pharmacodynamic feasibility-evaluable participants with measurable change in post-treatment tumor biology from baseline (Day 0 to Day 10 on-treatment biopsy)
Not provided in available filing data
- SEC filing section appears incomplete (contains only '6')
- No lead drug clearly identified - multiple drugs in trial without stated rationale for combination or prioritization
- No mechanism of action or target explicitly stated for the primary drug candidate
- No claimed differentiation provided
- No preclinical evidence summary
- No stated risks in available data
- Not provided in available filing data
- 2026-06-01Primary completion